Home » Topics » BioWorld Science

BioWorld Science
RSS

Phase III cohort of valoctocogene roxaparvovec meets criteria for regulatory review

May 28, 2019

FDA approves sNDA for Vraylar for bipolar depression

May 28, 2019

Medshine Discovery divulges IAP inhibitors

May 28, 2019

Paradigm reports new real-world data on iPPS in knee osteoarthritis

May 28, 2019

New PRMT5 inhibitors patented by Merck and collaborators

May 28, 2019

Bayer discloses PE inhibitors

May 28, 2019

FLX Bio presents new USP7 inhibitors

May 28, 2019

Massachusetts Institute of Technology patents MYC inhibitors

May 28, 2019

Ansun studies DAS-181 in phase III for lower tract PIV infections in immunocompromised patients

May 28, 2019

Newron delays start of phase II/III studies of evenamide for schizophrenia

May 28, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...